🟢 MetaVia is trading 5% up today on continued momentum for its obesity and cardiometabolic drug programs

MetaVia is trading 5% up at $1.87 amid continued interest in its obesity and cardiometabolic drug programs.

• Recent gains follow late-breaking abstract acceptances for DA-1726 and vanoglipel at the ADA 2026 Scientific Sessions.
• With no fresh company news today, the move appears to extend momentum in the thinly traded small-cap biotech name.
• Investors remain focused on the company’s obesity pipeline, which previously sparked a sharp rally.